




**Figure 1. Equilibrium binding of EZ-E-glucuronide to rhesus BBMVs**





**Figure 2. Equilibrium binding of EZE-glucuronide to rat BBMV.**



**Figure 3. Association and dissociation kinetics of  $^3\text{H}$ -EZE-glucuronide in rat BBMV.**

**B**

**B****A**

**Figure 5. Displacement of  $^3\text{H}$ -EZE-glucuronide by EZE-glucuronide and compound 2 in rhesus and rat BBMV.**






Figure 6. Displacement of  $^{35}\text{S}$ -labeled compound 2 by EZE-glucuronide and compound 2 in mouse BBMV.



**Figure 7. Intestinal distribution of ezetimibe binding sites.**







Figure 9. Displacement of  $^{35}\text{S}$ -labeled compound 2 by EZE-glucuronide and analogs in transfected CHO cells expressing human NPC1L1



**Figure 10.**  **$^{35}\text{S}$ -labeled compound 2 binding with brush border membranes from intestinal mucosal scrapings of male wild type (A) and NPC1L1 knockout (-/-) mice (B).**









Figure 11. Displacement of  $^{35}\text{S}$ -labeled compound **2** by compound **2** in mouse wild type and knockout mouse NPC1L1 (*-/-*) BBMV.

FIGURE 12

## Competition



**FIGURE 13****Panel 1****Panel 2**

**FIGURE 14**

**FIGURE 15**